vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v20i5.2312vsp-2757Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWНовая эра в лечении атопического дерматита: результаты длительного применения дупилумабаNew Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administrationhttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич - доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей; профессор кафедры дерматовенерологии и косметологии ЦГМА; профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова.119296, Москва, Ломоносовский пр-т, д. 2, стр. 1.Тел.: +7 (495) 967-14-20

Moscow.

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва.

Moscow.

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва.

Moscow.

https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

Москва.

Moscow.

https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchyanEduard T.

Москва.

Moscow.

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва.

Moscow.

https://orcid.org/0000-0001-9777-0156ФедоровД. В.FedorovDmitriy V.

Москва.

Moscow.

https://orcid.org/0000-0002-8268-069XКуколеваД. С.KukolevaDaria S.

Москва.

Moscow.

Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академияРоссияNational Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical AcademyRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children's HealthRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАНРоссияResearch Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”Russian Federation202107112021205390395Copyright © Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Федоров Д.В., Куколева Д.С., 20212021Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Федоров Д.В., Куколева Д.С.Murashkin N.N., Opryatin L.A., Epishev R.V., Materikin A.I., Ambarchyan E.T., Ivanov R.A., Fedorov D.V., Kukoleva D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2757

Атопический дерматит (АтД) — заболевание, характеризующееся хроническим воспалением кожи и дисфункцией эпидермального барьера, приводящими к снижению качества жизни пациентов. АтД широко распространен в популяции, включая детей. В статье обсуждены патофизиологические механизмы заболевания, в т.ч. в зависимости от эндотипа, рассмотрены основные принципы системной терапии детей со среднетяжелым и тяжелым течением АтД. Описаны особенности таргетной терапии таких пациентов ингибитором интерлейкинов IL-4 и -13 — препаратом дупилумаб. Приводится обзор результатов исследований эффективности и безопасности дупилумаба в кратко- и долгосрочной перспективе.

Atopic dermatitis (AD) is a disease characterized by chronic skin inflammation and epidermal barrier dysfunction leading to decrease in patients' quality of life. AD is widespread in general population including children. This article covers the disease pathophysiological mechanisms including those that depend on the endotype, as well as core principles of systemic therapy for children with moderate and severe AD. Features of targeted therapy of such patients with dupilumab (IL-4 and IL-13 inhibitor) are presented. The studies' results on dupilumab efficacy and safety in the short- and long-term are shown.

атопический дерматитэндотипыдупилумабдетиatopic dermatitisendotypesdupilumabchildrenНе указан.Not specified.ReferencesWeidinger S, Beck LA, Bieber I, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-zWeidinger S, Beck LA, Bieber I, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-zGandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-437. doi: 10.1080/1744666X.2017.1298443Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-437. doi: 10.1080/1744666X.2017.1298443Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. doi: 10.1016/j.jaci.2011.05.003Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. doi: 10.1016/j.jaci.2011.05.003Halvorsen JA, Lien L, Dalgard F, et al. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014;134(7):1847-1854. doi: 10.1038/jid.2014.70Halvorsen JA, Lien L, Dalgard F, et al. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014;134(7):1847-1854. doi: 10.1038/jid.2014.70Rhodes HL, Ihomas P, Sporik R, et al. A birth cohort study of subjects at risk of atopy: twenty-two-year follow-up of wheeze and atopic status. Am J Respir Crit Care Med. 2002;165(2):176-180. doi: 10.1164/ajrccm.165.2.2104032Rhodes HL, Ihomas P, Sporik R, et al. A birth cohort study of subjects at risk of atopy: twenty-two-year follow-up of wheeze and atopic status. Am J Respir Crit Care Med. 2002;165(2):176-180. doi: 10.1164/ajrccm.165.2.2104032Ekback M, Tedner M, Devenney I, et al. Severe eczema in infancy can predict asthma development: a prospective study to the age of 10 years. PLoS ONE. 2014;9(6):e99609. doi: 10.1371/journal.pone.0099609Ekback M, Tedner M, Devenney I, et al. Severe eczema in infancy can predict asthma development: a prospective study to the age of 10 years. PLoS ONE. 2014;9(6):e99609. doi: 10.1371/journal.pone.0099609Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388-398. doi: 10.1111/pde.12867Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388-398. doi: 10.1111/pde.12867Burgess JA, Dharmage SC, Byrnes GB, et al. Childhood eczema and asthma incidence and persistence: a cohort study from childhood to middle age. J Allergy Clin Immunol. 2008;122(2):280-285. doi: 10.1016/j.jaci.2008.05.018Burgess JA, Dharmage SC, Byrnes GB, et al. Childhood eczema and asthma incidence and persistence: a cohort study from childhood to middle age. J Allergy Clin Immunol. 2008;122(2):280-285. doi: 10.1016/j.jaci.2008.05.018Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605. doi: 10.1111/all.14318Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605. doi: 10.1111/all.14318Bieber T, Traidl-Hoffmann C, Schappi G, et al. Unraveling the complexity of atopic dermatitis: The CK-CARE approach toward precision medicine. Allergy. 2020;75(11):2936-2938. doi: 10.1111/all.14194Bieber T, Traidl-Hoffmann C, Schappi G, et al. Unraveling the complexity of atopic dermatitis: The CK-CARE approach toward precision medicine. Allergy. 2020;75(11):2936-2938. doi: 10.1111/all.14194Guttman-Yassky E, Waldman A, Ahluwalia J, et al. Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. 2017;36(3):100-103. doi: 10.12788/j.sder.2017.036Guttman-Yassky E, Waldman A, Ahluwalia J, et al. Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. 2017;36(3):100-103. doi: 10.12788/j.sder.2017.036Badloe FMS, De Vriese S, Coolens K, et al. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020;3(10):34. doi: 10.1186/s13601-020-00338-7Badloe FMS, De Vriese S, Coolens K, et al. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020;3(10):34. doi: 10.1186/s13601-020-00338-7Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis — PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-1358. doi: 10.1016/j.jaci.2016.03.010Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis — PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-1358. doi: 10.1016/j.jaci.2016.03.010Roesner LM, Heratizadeh A, Begemann G, et al. Der p1 and Der p2-Specific T Cells Display a Th2, Th17, and Th2/Th17 Phenotype in Atopic Dermatitis. J Invest Dermatol. 2015;135(9):2324-2327. doi: 10.1038/jid.2015.162Roesner LM, Heratizadeh A, Begemann G, et al. Der p1 and Der p2-Specific T Cells Display a Th2, Th17, and Th2/Th17 Phenotype in Atopic Dermatitis. J Invest Dermatol. 2015;135(9):2324-2327. doi: 10.1038/jid.2015.162Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032Schwartz C, Moran T, Saunders SP, et al. Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1₽. Allergy. 2019;74(10):1920-1933. doi: 10.1111/all.13801Schwartz C, Moran T, Saunders SP, et al. Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1₽. Allergy. 2019;74(10):1920-1933. doi: 10.1111/all.13801Jiao Q, Qian Q, Liu C, et al. T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator. Br J Dermatol. 2020;182(3):648-657. doi: 10.1111/bjd.18040Jiao Q, Qian Q, Liu C, et al. T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator. Br J Dermatol. 2020;182(3):648-657. doi: 10.1111/bjd.18040Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. Allergy. 2020;75(3):546-560. doi: 10.1111/all.14027Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. Allergy. 2020;75(3):546-560. doi: 10.1111/all.14027Dyjack N, Goleva E, Rios C, et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype. J Allergy Clin Immunol. 2018;141(4):1298-1309. doi: 10.1016/j.jaci.2017.10.046Dyjack N, Goleva E, Rios C, et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype. J Allergy Clin Immunol. 2018;141(4):1298-1309. doi: 10.1016/j.jaci.2017.10.046He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199-212. doi: 10.1016/j.jaci.2020.05.048He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199-212. doi: 10.1016/j.jaci.2020.05.048Pavel AB, Renert-Yuval Y, Wu J, et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesion-al skin. Allergy. 2021;76(1):314-325. doi: org/10.1111/all.14490Pavel AB, Renert-Yuval Y, Wu J, et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesion-al skin. Allergy. 2021;76(1):314-325. doi: org/10.1111/all.14490Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354. doi: 10.1016/j.jaci.2012.07.012Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354. doi: 10.1016/j.jaci.2012.07.012Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54-62. doi: 10.1111/all.13954Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54-62. doi: 10.1111/all.13954Yamanishi Y, Mogi K, Takahashi K, et al. Skin-infiltrating basophils promote atopic dermatitis- like inflammation via IL-4 production in mice. Allergy. 2020;75(10):2613-2622. doi: 10.1111/all.14362Yamanishi Y, Mogi K, Takahashi K, et al. Skin-infiltrating basophils promote atopic dermatitis- like inflammation via IL-4 production in mice. Allergy. 2020;75(10):2613-2622. doi: 10.1111/all.14362Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):eaax2945. doi: 10.1126/scitranslmed.aax2945Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):eaax2945. doi: 10.1126/scitranslmed.aax2945Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-228.e13. doi: 10.1016/j.cell.2017.08.006Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-228.e13. doi: 10.1016/j.cell.2017.08.006Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840-1852. doi: 10.1016/j.jaip.2020.02.022Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840-1852. doi: 10.1016/j.jaip.2020.02.022Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1):99-110.e6. doi: 10.1016/j.anai.2018.08.024Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1):99-110.e6. doi: 10.1016/j.anai.2018.08.024Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254-1264. doi: 10.1016/j.jaci.2015.08.015Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254-1264. doi: 10.1016/j.jaci.2015.08.015Margolis DJ, Mitra N, Wubbenhorst B, et al. Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis. JAMA Dermatol. 2019;155(11):1269-1276. doi: 10.1001/jamadermatol.2019.1946Margolis DJ, Mitra N, Wubbenhorst B, et al. Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis. JAMA Dermatol. 2019;155(11):1269-1276. doi: 10.1001/jamadermatol.2019.1946Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094-2106. doi: 10.1016/j.jaci.2018.02.040Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094-2106. doi: 10.1016/j.jaci.2018.02.040Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: 10.1111/jdv.14891Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: 10.1111/jdv.14891Proudfoot LE, Powell AM, Ayis S, et al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol. 2013;169(4):901-909. doi: 10.1111/bjd.12505Proudfoot LE, Powell AM, Ayis S, et al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol. 2013;169(4):901-909. doi: 10.1111/bjd.12505Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol. 2017;76(2):281-285. doi: 10.1016/j.jaad.2016.09.021Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol. 2017;76(2):281-285. doi: 10.1016/j.jaad.2016.09.021Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: 10.1111/jdv.14888Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: 10.1111/jdv.14888Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197(6):703-709. doi: 10.1084/jem.20020906Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197(6):703-709. doi: 10.1084/jem.20020906Ungar B, Garcet S, Gonzalez J. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest Dermatol. 2017;137(3):603-613. doi: 10.1016/j.jid.2016.09.037Ungar B, Garcet S, Gonzalez J. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest Dermatol. 2017;137(3):603-613. doi: 10.1016/j.jid.2016.09.037Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129-2139. doi: 10.1080/21645515.2019.1582403Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129-2139. doi: 10.1080/21645515.2019.1582403Harb H, Chatila T. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5-14. doi: 10.1111/cea.13491Harb H, Chatila T. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5-14. doi: 10.1111/cea.13491Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate‐to‐severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate‐to‐severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo‐controlled, dose‐ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo‐controlled, dose‐ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi: 10.1056/NEJMoa1610020Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi: 10.1056/NEJMoa1610020Castro M, Corren J, Pavord I, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. doi: 10.1056/NEJMoa1804092Castro M, Corren J, Pavord I, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. doi: 10.1056/NEJMoa1804092Rabe K, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. doi: 10.1056/NEJMoa1804093Rabe K, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. doi: 10.1056/NEJMoa1804093Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1Beck LA, Thag D, Deleuran M, et al. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2020;21(4):567-577. doi: 10.1007/s40257-020-00527-xBeck LA, Thag D, Deleuran M, et al. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2020;21(4):567-577. doi: 10.1007/s40257-020-00527-xDeleuran M, Thaçi D, Beck LA, et al. Dupilumab shows longterm safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi: 10.1016/j.jaad.2019.07.074Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows longterm safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi: 10.1016/j.jaad.2019.07.074Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension. Br J Dermatol. 2020;182(1):85–96. doi: 10.1111/bjd.18476Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension. Br J Dermatol. 2020;182(1):85–96. doi: 10.1111/bjd.18476Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, doubleblinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi: 10.1016/j.jaad.2020.06.054Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, doubleblinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi: 10.1016/j.jaad.2020.06.054Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464-475. doi: 10.1111/jdv.16928Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464-475. doi: 10.1111/jdv.16928

The authors declare that there are no conflicts of interest present.